Sugi Predict

Sugi Predict / Compounds / SCHEMBL18920679

SCHEMBL18920679

SCHEMBL18920679

COC(=O)c1cc(Br)c(OC)cc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ LCK P06239 1/20 0.44
▸ FYN P06241 1/20 0.44
▸ GAA P10253 4/20 0.44
▸ MAPT P10636 4/20 0.44
▸ LMNA P02545 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ POLB P06746 4/20 0.44
▸ HPGD P15428 3/20 0.43
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ SOS1 Q07889 1/20 0.41
▸ HSD17B10 Q99714 3/20 0.41
▸ USP2 O75604 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29928120 0.93 KDM4E (0.51) KDM4EALDH1A1LCKFYNGAA
SCHEMBL25134261 0.93 KDM4E (0.51) KDM4EALDH1A1LCKFYNGAA
SCHEMBL30447954 0.87 KDM4E (0.56) KDM4EALDH1A1LCKFYNGAA
SCHEMBL25341632 0.87 KDM4E (0.56) KDM4EALDH1A1LCKFYNGAA
SCHEMBL166802 0.86 GAA (0.50) KDM4EALDH1A1LCKFYNGAA
SCHEMBL383036 0.85 GAA (0.53) KDM4EALDH1A1LCKFYNGAA
SCHEMBL3972997 0.85 KDM4E (0.63) KDM4EALDH1A1GAAMAPTLMNA
SCHEMBL1539191 0.84 LCK (0.59) KDM4EALDH1A1LCKFYNMAPT
SCHEMBL1539328 0.84 ALDH1A1 (0.49) ALDH1A1LCKFYNMAPTLMNA
SCHEMBL30107294 0.83 NOTUM (0.45) KDM4EALDH1A1GAAMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098030-A1 NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 UNIV VANDERBILT (US) 2026-04-09 — — US disclosed
WO-2025262433-A1 N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2025-12-26 — — WO disclosed
EP-4656642-A1 ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF GAN & LEE PHARM CO., LTD (CN) 2025-12-03 — — EP disclosed
EP-4568944-A1 NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 Vanderbilt University (US) 2025-06-18 — — EP disclosed
US-20250129088-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR GAN & LEE PHARMACEUTICALS CO., LTD. (CN) 2025-04-24 — — US disclosed
WO-2025026283-A1 COMPOUND FOR SELECTIVELY DEGRADING SMARCA2/4 AND USE THEREOF 甘李药业股份有限公司 2025-02-06 — — WO disclosed
EP-4471033-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR Gan & Lee Pharmaceuticals Co., Ltd. (CN) 2024-12-04 — — EP disclosed
WO-2024178390-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2024-08-29 — — WO disclosed
WO-2024156294-A1 ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF 甘李药业股份有限公司 2024-08-02 — — WO disclosed
WO-2024146617-A1 COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR 甘李药业股份有限公司 2024-07-11 — — WO disclosed
CN-117858707-A CBL-B modulators and uses thereof 林伯士克莱奥公司 2024-04-09 — — CN disclosed
WO-2024059781-A1 NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 VANDERBILT UNIVERSITY (US) 2024-03-21 — — WO disclosed
WO-2023143589-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR 甘李药业股份有限公司 2023-08-03 — — WO disclosed
US-10654818-B2 Furane derivatives as inhibitors of ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-19 — — US disclosed
EP-3383865-B1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 Bayer Pharma AG (DE) 2020-01-29 — — EP disclosed
US-20190218196-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-07-18 — — US disclosed
EP-3383865-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 Bayer Pharma Aktiengesellschaft (DE) 2018-10-10 — — EP disclosed
WO-2018089499-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-05-17 — — WO disclosed
US-20180127370-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2018-05-10 — — US disclosed
WO-2017093272-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129088-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR CRBN, UBE3A, UBE3C KDM4E 1439/4885ALDH1A1 3364/4885LCK 4356/4885
US-20190218196-A1 FURANE DERIVATIVES AS INHIBITORS OF ATAD2 ATAD2, ATAD2B, TAF1L KDM4E 407/4885ALDH1A1 1538/4885LCK 3147/4885
US-20260098030-A1 NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 GRM2, GRM1, GRIN2C KDM4E 2244/4885ALDH1A1 1683/4885LCK 2237/4885
US-20180127370-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF MTOR, RICTOR, RPTOR KDM4E 253/4885ALDH1A1 3942/4885LCK 899/4885
US-10654818-B2 Furane derivatives as inhibitors of ATAD2 ATAD2, ATAD2B, TAF1L KDM4E 407/4885ALDH1A1 1538/4885LCK 3147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.